- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03443089
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Comparative Bioavailability Study of Two Injectable Suspension Formulations, a Test (Medroxyprogesterone Acetate 25 mg/mL + Estradiol Cypionate 5 mg/mL) vs. a Reference (Medroxyprogesterone Acetate 25 mg/AMP + Estradiol Cypionate 5 mg/AMP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was performed in a monocentric, open label, parallel design, with 2 treatments, 1 period, in which twelve subjects received the test product (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and twelve subjects received the reference product (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.). The formulations (test or reference) were administered in a single intramuscular dose (1 ampoule) after an overnight fast (approximately 8 h). Blood samples (9 mL) were collected via a venous catheter into heparinized tubes at times pre-dose (0 h) and 6, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848, and 2016 h after drug administration to measure medroxyprogesterone; and pre-dose (-48, -24 and 0 h) e 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, and 1008 h after drug administration to measure estradiol cypionate.
The safety assessment was based on recording adverse events throughout the study duration. The subjects systolic and diastolic pressures, heart rate and temperature were determined prior and at approximately 4, 8 and 12 h after drug administration. The clinical evaluation and the laboratory tests were also performed at the end of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
SP
-
Campinas, SP, Brazil
- Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body-mass index (BMI) ≥19.0 kg/m² and ≤ 27.5 kg/m²
- With regular cycles, without use of hormonal contraceptives (pills at least 3 months and injectables at least 1 year) and not using hormone replacement therapy
- Not pregnant or breastfeeding
- Good state of health
- Non-smoker or ex-smoker for at least 6 month
- Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial
Exclusion Criteria:
- Existing cardiac, hepatic and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability and/or pharmacokinetics and/or pharmacodynamics of the active ingredient
- History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
- Subjects with severe allergies or multiple drug allergies, unless it is judged as not relevant for the clinical trial by the investigator
- Positive anti-HIV-test (if positive to be verified by western blot), HBs-AGtest (if positive to be verified by test for HBc-IgM) or anti-HCV-test
- Admitted for any reason up to 8 weeks before the start of the first treatment period of this study
- History of or current drug or alcohol dependence
- Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
- Regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
- Blood donation or other blood loss of more than 400 ml within the last 3 months prior to individual enrolment of the subject
- Participation in a clinical trial during the last 6 months prior to individual enrolment of the subject
- Positive pregnancy test, delivery or abortion in the 12 weeks prior to the planned hospitalization date.
- Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Test formulation
Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
|
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
|
ACTIVE_COMPARATOR: Reference formulation
Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
|
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of medroxyprogesterone acetate and estradiol cypionate plasma levels
Time Frame: 0-1008 hours after drug administration
|
Blood sampling for the determination of plasma levels of medroxyprogesterone acetate and estradiol cypionate in participants of each treatment group.
|
0-1008 hours after drug administration
|
Measurement of estradiol cypionate plasma levels
Time Frame: -48 to 1008 hours after drug administration
|
Blood sampling for the determination of plasma levels of estradiol cypionate in participants of each treatment group.
|
-48 to 1008 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of medroxyprogesterone acetate
Time Frame: 0 - 1008 hours after drug administration
|
Determination of maximum plasma concentration of medroxyprogesterone acetate on plasma concentrations of samples obtained.
|
0 - 1008 hours after drug administration
|
Maximum Plasma Concentration (Cmax) of estradiol cypionate
Time Frame: 0 - 1008 hours after drug administration
|
Determination of maximum plasma concentration of estradiol cypionate on plasma concentrations of samples obtained.
|
0 - 1008 hours after drug administration
|
Area Under the Curve (AUC) of medroxyprogesterone acetate
Time Frame: 0 - 1008 hours after drug administration
|
Determination of area Under the Curve of medroxyprogesterone acetate from plasma concentrations versus time curve of samples obtained.
|
0 - 1008 hours after drug administration
|
Area Under the Curve (AUC) of estradiol cypionate
Time Frame: 0 - 1008 hours after drug administration
|
Determination of area Under the Curve of estradiol cypionate from plasma concentrations versus time curves of samples obtained.
|
0 - 1008 hours after drug administration
|
Number of adverse events per participant
Time Frame: Up to 1008 hours after drug administration
|
Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results.
|
Up to 1008 hours after drug administration
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GDN 022/16
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Test formulation
-
Alcon ResearchCompleted
-
Eli Lilly and CompanyCompletedHealthy ParticipantsSingapore
-
Astellas Pharma Global Development, Inc.CompletedHealthy VolunteersUnited States
-
Assembly BiosciencesCompletedChronic Hepatitis BUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
GlaxoSmithKlineCompletedProstatic HyperplasiaBrazil
-
GlaxoSmithKlineCompletedProstatic HyperplasiaBrazil
-
Janssen Research & Development, LLCCompleted